These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 37026045)

  • 21. Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems.
    Cunha S; Amaral MH; Lobo JM; Silva AC
    Curr Med Chem; 2016; 23(31):3618-3631. PubMed ID: 27554805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood-Brain Barrier and Neurodegenerative Diseases-Modeling with iPSC-Derived Brain Cells.
    Wu YC; Sonninen TM; Peltonen S; Koistinaho J; Lehtonen Š
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic nanoplatforms and delivery strategies for neurological disorders.
    Kang YJ; Cutler EG; Cho H
    Nano Converg; 2018 Nov; 5(1):35. PubMed ID: 30499047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
    Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Research on Pro-drug Therapies for Parkinson's and Alzheimer's Disease.
    Huo C; Wu L; Jiang Z; Yang J; Wang Z; Li Y; Qian S
    Med Chem; 2022; 18(6):655-666. PubMed ID: 34847848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between CNS-active drugs and risk of Alzheimer's and age-related neurodegenerative diseases.
    Cortes-Flores H; Torrandell-Haro G; Brinton RD
    Front Psychiatry; 2024; 15():1358568. PubMed ID: 38487578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Limitations in the Treatment of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers.
    Tonda-Turo C; Origlia N; Mattu C; Accorroni A; Chiono V
    Curr Med Chem; 2018; 25(41):5755-5771. PubMed ID: 29473493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential Gene Therapy Towards Treating Neurodegenerative Disea ses Employing Polymeric Nanosystems.
    Bangde P; Atale S; Dey A; Pandit A; Dandekar P; Jain R
    Curr Gene Ther; 2017; 17(2):170-183. PubMed ID: 28494742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases.
    Bravo-Vázquez LA; Mora-Hernández EO; Rodríguez AL; Sahare P; Bandyopadhyay A; Duttaroy AK; Paul S
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Titania coating of mesoporous silica nanoparticles for improved biocompatibility and drug release within blood vessels.
    Farooq A; Shukur A; Astley C; Tosheva L; Kelly P; Whitehead D; Azzawi M
    Acta Biomater; 2018 Aug; 76():208-216. PubMed ID: 29933106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies.
    Goel H; Kalra V; Verma SK; Dubey SK; Tiwary AK
    J Control Release; 2022 Jan; 341():782-811. PubMed ID: 34906605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitochondria targeting drugs for neurodegenerative diseases-Design, mechanism and application.
    Xu J; Du W; Zhao Y; Lim K; Lu L; Zhang C; Li L
    Acta Pharm Sin B; 2022 Jun; 12(6):2778-2789. PubMed ID: 35755284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of Nanocomposites and Nanoparticles in Treating Neurodegenerative Disorders.
    Fatima J; Siddique YH
    CNS Neurol Disord Drug Targets; 2024 Jan; ():. PubMed ID: 38288843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mesoporous Silica Platforms with Potential Applications in Release and Adsorption of Active Agents.
    Chircov C; Spoială A; Păun C; Crăciun L; Ficai D; Ficai A; Andronescu E; Turculeƫ ȘC
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32825791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mesoporous Silica Nanoparticles: Types, Synthesis, Role in the Treatment of Alzheimer's Disease, and Other Applications.
    Sivamaruthi BS; Kapoor DU; Kukkar RR; Gaur M; Elossaily GM; Prajapati BG; Chaiyasut C
    Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual response to pH and chiral microenvironments for the release of a flurbiprofen-loaded chiral self-assembled mesoporous silica drug delivery system.
    Wu L; Gou K; Guo X; Guo Y; Chen M; Hou J; Li S; Li H
    Colloids Surf B Biointerfaces; 2021 Mar; 199():111501. PubMed ID: 33338882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS.
    Gondim BLC; da Silva Catarino J; de Sousa MAD; de Oliveira Silva M; Lemes MR; de Carvalho-Costa TM; de Lima Nascimento TR; Machado JR; Rodrigues V; Oliveira CJF; Cançado Castellano LR; da Silva MV
    Curr Pharm Des; 2019; 25(37):3983-3996. PubMed ID: 31612822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural Compounds Preventing Neurodegenerative Diseases Through Autophagic Activation.
    Huang Z; Adachi H
    J UOEH; 2016 Jun; 38(2):139-48. PubMed ID: 27302727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Natural Compounds on Neurodegenerative Disorders: From Preclinical to Pharmacotherapeutics.
    Sharifi-Rad M; Lankatillake C; Dias DA; Docea AO; Mahomoodally MF; Lobine D; Chazot PL; Kurt B; Tumer TB; Moreira AC; Sharopov F; Martorell M; Martins N; Cho WC; Calina D; Sharifi-Rad J
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32276438
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.